D
Danielle Blunt
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
NOV 9
NOV 16
Oct 19, 2026
Molecular residual disease (MRD) in monitoring PTCL | PETAL Podcast Episode 4
J
12:15Julia ZhangHOST
So Daniel, what are the methods of measuring ctDNA that are out commercially available or in research available? And what are the methods that look most promising to you in PTCL?
D
12:32Danielle BluntGUEST
I think the ctDNA is probably the most broadly applicable approach with next-generation sequencing used to identify and track tumor-derived variants in the plasma.
D
12:44Danielle BluntGUEST
But we know that PTCL is such a heterogeneous disease and offers a lot of biological challenges.
D
12:56Danielle BluntGUEST
So one approach is to do the next generation sequencing of the ctDNA where you identify mutations associated with the lymphoma, and then you can track those longitudinally in the plasma.
D
13:08Danielle BluntGUEST
The difficulty with this is making sure that the signal that you're actually following belongs to the lymphoma.
D
13:15Danielle BluntGUEST
And a really good example in peripheral T cell is neural T follicular helper cell lymphomas, where we know that there's a lot of more myeloid-based mutations that can be driving clonal hematopoiesis in the background, mutations such as TET2, DNM T3A, Rho A, IDH2.
12 MINS LATER